301–1228 Hamilton Street
Vancouver, BC V6B 6L2
Full Time Employees:
|Mr. Michael E. McFadden||CEO & Director||429.78k||N/A||1967|
|Mr. Kenneth Anthony Cawkell B.A., LL.B.||Founder, Special Advisor, Corp. Sec. & Director||264.6k||N/A||1951|
|Dr. Denis G. Kay Ph.D.||Chief Scientific Officer||238.57k||N/A||1957|
|Ms. Lauren D'Angelo M.B.A.||Chief Commercial Officer||312.4k||N/A||N/A|
|Mr. Donald A. Kalkofen B.A.||Chief Financial Officer||N/A||N/A||1964|
|Ms. Colleen Johns||Sr. VP of Product Devel.||N/A||N/A||N/A|
|Dr. Cedric O'Gorman M.B.A., M.D., MBA||Chief Medical Officer||N/A||N/A||1975|
Alpha Cognition Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062, an acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer's type and mild traumatic brain injury; and ALPHA-0602, a gene therapy for the treatment of ALS. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.
Alpha Cognition Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.